1.36
-0.02(-1.45%)
Currency In USD
| Previous Close | 1.38 |
| Open | 1.38 |
| Day High | 1.38 |
| Day Low | 1.32 |
| 52-Week High | 3.33 |
| 52-Week Low | 1.01 |
| Volume | 556,537 |
| Average Volume | 709,743 |
| Market Cap | 98.26M |
| PE | -0.65 |
| EPS | -2.08 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 1.45 |
| Change | -0.02 |
If you invested $1000 in Zentalis Pharmaceuticals, Inc. (ZNTL) since IPO date, it would be worth $58.62 as of December 29, 2025 at a share price of $1.36. Whereas If you bought $1000 worth of Zentalis Pharmaceuticals, Inc. (ZNTL) shares 3 years ago, it would be worth $73.91 as of December 29, 2025 at a share price of $1.36.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
GlobeNewswire Inc.
Aug 26, 2025 8:05 PM GMT
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertiseSAN DIEGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
GlobeNewswire Inc.
Apr 28, 2025 12:00 PM GMT
Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback SAN DIEGO, April 28, 2025 (GLOBE